GLENMARK PHARMACEUTICALS
Back to Balance Sheet
|
GLENMARK PHARMACEUTICALS Last 5 Year Total Non-Current Liabilities History
[Consolidated]
Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
---|---|---|---|---|---|
Total Non-Current Liabilities | ₹-357 Cr | ₹2,621 Cr | ₹1,270 Cr | ₹2,804 Cr | ₹3,033 Cr |
What is the latest Total Non-Current Liabilities ratio of GLENMARK PHARMACEUTICALS ?
Year | Total Non-Current Liabilities |
---|---|
Mar2024 | ₹-357 Cr |
Mar2023 | ₹2,621 Cr |
Mar2022 | ₹1,270 Cr |
Mar2021 | ₹2,804 Cr |
Mar2020 | ₹3,033 Cr |
How is Total Non-Current Liabilities of GLENMARK PHARMACEUTICALS Trending?
Years | Total Non-Current Liabilities | % Change | |
---|---|---|---|
Mar2024 | ₹-357 Cr | Negative | |
Mar2023 | ₹2,621 Cr | 106.48 | |
Mar2022 | ₹1,270 Cr | -54.72 | |
Mar2021 | ₹2,804 Cr | -7.56 | |
Mar2020 | ₹3,033 Cr | - |
Compare Total Non-Current Liabilities of peers of GLENMARK PHARMACEUTICALS
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
GLENMARK PHARMACEUTICALS | ₹40,729.9 Cr | 1.9% | 4.8% | 41.7% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹409,818.0 Cr | -3.3% | 3.4% | 13.9% | Stock Analytics | |
DIVIS LABORATORIES | ₹164,628.0 Cr | 4.1% | 15.2% | 60.2% | Stock Analytics | |
CIPLA | ₹120,775.0 Cr | 0.6% | 5.6% | 11.8% | Stock Analytics | |
TORRENT PHARMACEUTICALS | ₹109,758.0 Cr | 1.9% | 3.7% | 28.2% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹101,791.0 Cr | 6.2% | 11.4% | 2.6% | Stock Analytics |
GLENMARK PHARMACEUTICALS Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
GLENMARK PHARMACEUTICALS | 1.9% |
4.8% |
41.7% |
SENSEX | 0.7% |
9.6% |
10.7% |
You may also like the below Video Courses